The TTLL1 (tubulin tyrosine ligase-like 1) antibody targets a protein belonging to the tubulin tyrosine ligase-like family, which is involved in post-translational modification of tubulins. TTLL1 specifically catalyzes the initiation of polyglutamylation, a process that adds glutamate chains to tubulin’s C-terminal tails, influencing microtubule stability, intracellular transport, and cilia function. This enzymatic activity plays critical roles in cellular processes such as mitosis, neuronal development, and cilia assembly. Dysregulation of TTLL1 has been linked to neurodegenerative disorders, ciliopathies, and cancer progression. Antibodies against TTLL1 are essential tools for studying its expression, localization, and function in various tissues. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate TTLL1’s role in disease models or genetic studies. Research has highlighted its potential as a biomarker or therapeutic target, particularly in cancers like glioblastoma and prostate cancer, where abnormal polyglutamylation correlates with aggressiveness. Validated TTLL1 antibodies help elucidate mechanisms underlying microtubule-related pathologies and contribute to drug discovery efforts aimed at modulating polyglutamylation pathways.